Cargando…

Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

PURPOSE: Similar to the neutrophil-to-lymphocyte ratio and lung immune prognostic index (LIPI), immune-related adverse events (irAEs) were favorable prognostic factors in several studies, for patients with non-small cell lung cancer who received immune checkpoint inhibitors (ICIs). However, few stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Sonehara, Kei, Tateishi, Kazunari, Araki, Taisuke, Komatsu, Masamichi, Akahane, Jumpei, Yamamoto, Hiroshi, Hanaoka, Masayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818764/
https://www.ncbi.nlm.nih.gov/pubmed/35140520
http://dx.doi.org/10.2147/CMAR.S347852
_version_ 1784645901836353536
author Sonehara, Kei
Tateishi, Kazunari
Araki, Taisuke
Komatsu, Masamichi
Akahane, Jumpei
Yamamoto, Hiroshi
Hanaoka, Masayuki
author_facet Sonehara, Kei
Tateishi, Kazunari
Araki, Taisuke
Komatsu, Masamichi
Akahane, Jumpei
Yamamoto, Hiroshi
Hanaoka, Masayuki
author_sort Sonehara, Kei
collection PubMed
description PURPOSE: Similar to the neutrophil-to-lymphocyte ratio and lung immune prognostic index (LIPI), immune-related adverse events (irAEs) were favorable prognostic factors in several studies, for patients with non-small cell lung cancer who received immune checkpoint inhibitors (ICIs). However, few studies have investigated patient characteristics and markers that predict the development of irAEs, and factors predicting the development of irAEs have not been clarified. Thus, the present study aimed to examine the predictive factors correlated with the development of irAEs in non-small cell lung cancer (NSCLC) patients who received anti-programmed cell death protein 1/programmed cell death ligand 1 inhibitor monotherapy. PATIENTS AND METHODS: The present study was retrospectively enrolled 113 advanced NSCLC patients who received ICIs between February 2016 and May 2021 and was conducted at Shinshu University Hospital. All patients were divided into two groups according to with or without of irAEs. We compared the clinical findings and laboratory data between the two groups and considered predictive factors correlated with the development of irAEs. RESULTS: Forty-four (38.9%) patients developed irAEs of any grade. The most common irAEs were hypothyroidism (12.4%), followed by skin rash (7.1%) and interstitial lung disease (7.1%). The survival time in patients with irAEs was significantly more prolonged compared to those without irAEs (median progression-free survival: 6.8 vs 2.1 months, p < 0.001; median overall survival: 25.3 vs 9.6 months, p = 0.001). Multivariate analyses based on logistic regression revealed independent predictive factors that correlated with the development of irAEs to be first-line ICI treatment and a score of 0 or 1 on LIPI. CONCLUSION: The present study revealed that lines of immunotherapy and LIPI were correlated with the development of irAEs in NSCLC patients who received ICIs and can help clinicians who manage patients experiencing irAEs receiving ICIs.
format Online
Article
Text
id pubmed-8818764
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-88187642022-02-08 Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors Sonehara, Kei Tateishi, Kazunari Araki, Taisuke Komatsu, Masamichi Akahane, Jumpei Yamamoto, Hiroshi Hanaoka, Masayuki Cancer Manag Res Original Research PURPOSE: Similar to the neutrophil-to-lymphocyte ratio and lung immune prognostic index (LIPI), immune-related adverse events (irAEs) were favorable prognostic factors in several studies, for patients with non-small cell lung cancer who received immune checkpoint inhibitors (ICIs). However, few studies have investigated patient characteristics and markers that predict the development of irAEs, and factors predicting the development of irAEs have not been clarified. Thus, the present study aimed to examine the predictive factors correlated with the development of irAEs in non-small cell lung cancer (NSCLC) patients who received anti-programmed cell death protein 1/programmed cell death ligand 1 inhibitor monotherapy. PATIENTS AND METHODS: The present study was retrospectively enrolled 113 advanced NSCLC patients who received ICIs between February 2016 and May 2021 and was conducted at Shinshu University Hospital. All patients were divided into two groups according to with or without of irAEs. We compared the clinical findings and laboratory data between the two groups and considered predictive factors correlated with the development of irAEs. RESULTS: Forty-four (38.9%) patients developed irAEs of any grade. The most common irAEs were hypothyroidism (12.4%), followed by skin rash (7.1%) and interstitial lung disease (7.1%). The survival time in patients with irAEs was significantly more prolonged compared to those without irAEs (median progression-free survival: 6.8 vs 2.1 months, p < 0.001; median overall survival: 25.3 vs 9.6 months, p = 0.001). Multivariate analyses based on logistic regression revealed independent predictive factors that correlated with the development of irAEs to be first-line ICI treatment and a score of 0 or 1 on LIPI. CONCLUSION: The present study revealed that lines of immunotherapy and LIPI were correlated with the development of irAEs in NSCLC patients who received ICIs and can help clinicians who manage patients experiencing irAEs receiving ICIs. Dove 2022-02-02 /pmc/articles/PMC8818764/ /pubmed/35140520 http://dx.doi.org/10.2147/CMAR.S347852 Text en © 2022 Sonehara et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Sonehara, Kei
Tateishi, Kazunari
Araki, Taisuke
Komatsu, Masamichi
Akahane, Jumpei
Yamamoto, Hiroshi
Hanaoka, Masayuki
Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
title Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
title_full Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
title_fullStr Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
title_full_unstemmed Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
title_short Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors
title_sort predictive factors correlated with the development of immune-related adverse events in patients with non-small cell lung cancer treated with immune checkpoint inhibitors
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8818764/
https://www.ncbi.nlm.nih.gov/pubmed/35140520
http://dx.doi.org/10.2147/CMAR.S347852
work_keys_str_mv AT soneharakei predictivefactorscorrelatedwiththedevelopmentofimmunerelatedadverseeventsinpatientswithnonsmallcelllungcancertreatedwithimmunecheckpointinhibitors
AT tateishikazunari predictivefactorscorrelatedwiththedevelopmentofimmunerelatedadverseeventsinpatientswithnonsmallcelllungcancertreatedwithimmunecheckpointinhibitors
AT arakitaisuke predictivefactorscorrelatedwiththedevelopmentofimmunerelatedadverseeventsinpatientswithnonsmallcelllungcancertreatedwithimmunecheckpointinhibitors
AT komatsumasamichi predictivefactorscorrelatedwiththedevelopmentofimmunerelatedadverseeventsinpatientswithnonsmallcelllungcancertreatedwithimmunecheckpointinhibitors
AT akahanejumpei predictivefactorscorrelatedwiththedevelopmentofimmunerelatedadverseeventsinpatientswithnonsmallcelllungcancertreatedwithimmunecheckpointinhibitors
AT yamamotohiroshi predictivefactorscorrelatedwiththedevelopmentofimmunerelatedadverseeventsinpatientswithnonsmallcelllungcancertreatedwithimmunecheckpointinhibitors
AT hanaokamasayuki predictivefactorscorrelatedwiththedevelopmentofimmunerelatedadverseeventsinpatientswithnonsmallcelllungcancertreatedwithimmunecheckpointinhibitors